(C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.”
“Purpose: We determined the role of factor inhibiting hypoxia-inducible factor-1 in prostate cancer specimens.

Materials and Methods: A tissue microarray of 152 prostate cancers was constructed and stained for factor inhibiting hypoxia-inducible factor-1, hypoxiainducible factor-1 alpha and 2 alpha, and glucose transporter 1 as a prototypical downstream target of AR-13324 research buy hypoxia-inducible factor-1 alpha. Correlation analysis was done between these variables,

and between factor inhibiting hypoxia-inducible factor-1, and clinical and pathological variables, including prostate specific antigen as a surrogate of recurrence.

Results: Factor inhibiting hypoxia-inducible factor-1 was expressed in the cytoplasm and/or the nucleus in 86.5% of tumors, including exclusive cytoplasmic expression Necrostatin-1 in 51.3% and exclusive nuclear expression in 5.3%. Any nuclear and exclusive expression of factor inhibiting hypoxia-inducible factor was associated with poor prognosis on univariate analysis (p = 0.007 and 0.042, respectively). On

multivariate analysis men with nuclear expression in tumors were twice as likely to experience recurrence (p = 0.034).

Conclusions: Factor inhibiting hypoxia-inducible factor-1 is widely expressed in prostate tumors. Its differential subcellular expression suggests that regulation of its expression is an important factor in the activity of the hypoxia-inducible factor pathway. Its modulation may help treat hypoxia-inducible factor driven aggressive prostate cancer.”
“Previous studies show that most short thoracic propriospinal (TPS; T5-T7) and long descending propriospinal

tract (LDPT; C4-C6) neurons are lost following low-thoracic spinal cord contusion injury (cSCI), as assessed by retrograde labeling with fluorogold (FG). Gene microarray and terminal deoxynucleotidyl transferase dUTP nick end (TUNEL)/caspase-3 immunolabeling indicate that post-axotomy cell death may be responsible for the observed decrease in number of labeled TPS neurons post cSCI. Yet, no indications of post-axotomy cell death are evident within LDPT neurons following the same injury. The present experiments were devised to understand this difference. Evofosfamide clinical trial We assessed the number and size of LDPT and TPS neurons at different time points, retrogradely labeling these neurons with FG prior to delivering a moderate low-thoracic cSCI or after they were axotomized by a complete low-thoracic spinal transection. Counts of FG-filled TPS and LDPT cells indicate a large loss of both neuronal populations 2 weeks post cSCI. Propriospinal neurons in other animals were retrogradely labeled with dextran tetramethyl rhodamine prior to cSCI and tissue was processed for detection of TUNEL- or caspase-3-positive profiles at chronic times post injury.